0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$270.00
This product is available by prescription only
This product does not require a prescription
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
The 30mg vial provides high peptide availability for simultaneous multi-protocol or multi-arm study designs, reducing vial requirements and simplifying laboratory inventory management across extended research programs. Lyophilized powder format ensures long-term stability for multi-year institutional protocols, supporting consistent experimental conditions and reproducible molecular endpoint data throughout the observation period.
Tirzepatide co-activates glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors — two structurally related but pharmacologically distinct incretin system G-protein-coupled receptors. GIP receptor activation is studied in relation to glucose-dependent insulin secretion pathway signaling and pancreatic beta-cell cAMP marker activity. GLP-1 receptor activation is studied for its association with glucagon suppression pathway dynamics and insulin secretion assay endpoints. Dual receptor agonism enables researchers to examine interaction effects between these two incretin signaling axes and whether simultaneous activation produces additive or synergistic downstream molecular marker responses compared to single-receptor reference compounds.
Produced by Elivena in USA GMP-certified facilities to approximately 99% purity, each 30mg vial is independently verified by COA documentation confirming sequence identity, purity grade, and batch-specific quality control data. This level of characterization supports institutional compliance requirements and provides professional laboratories with reliable, pharmaceutical-grade dual-agonist material for regulatory-documentation-quality research records.
Tirzepatide 30mg is suited for professional laboratories and university research programs conducting advanced, long-duration dual-agonist receptor pharmacology investigations. Research teams examining GIP and GLP-1 receptor interaction dynamics, comparative incretin pathway signaling studies, or complex multi-arm metabolic endpoint characterization protocols benefit from this high-concentration format. The 30mg vial supports multi-phase institutional research designs where consistent high-volume peptide availability reduces procurement complexity and supports uninterrupted protocol execution over extended observation periods. Produced by Elivena in USA GMP-certified facilities, each vial is COA-verified for purity and sequence identity to approximately 99%.
Tirzepatide supports in-vitro investigation of simultaneous GIP and GLP-1 receptor binding kinetics, receptor occupancy dynamics, and competitive binding assay endpoint characterization in pancreatic cell line and primary culture models. Researchers examining dual-receptor selectivity profiles, binding affinity parameters, and receptor subtype interaction dynamics use Tirzepatide as a primary reference agonist for comparative incretin receptor pharmacology study designs.
Laboratories studying incretin pathway signal transduction use Tirzepatide to quantify downstream molecular marker activity, including cAMP second messenger elevation, PKA phosphorylation cascade dynamics, insulin secretion assay output, and glucagon suppression pathway marker expression in controlled preclinical metabolic models. Multi-arm protocols comparing dual-receptor and single-receptor agonist effects on these endpoints support mechanistic characterization of incretin pathway interaction at the molecular level.
The 30mg concentration supports extended 52–104 week experimental programs examining longitudinal dual-receptor signaling pathway marker progression, dose-response relationship characterization, and multi-arm comparative metabolic endpoint analysis. Professional laboratories managing multiple concurrent dual-agonist protocols benefit from the operational efficiency this concentration provides, supporting consistent peptide availability and reproducible experimental conditions across all study phases.
The 30mg vial provides sufficient material to support full dose escalation study designs — from low initial concentrations through maintenance-level dosing ranges — within a single procurement cycle. Laboratories investigating dose-dependent receptor pathway activation kinetics, threshold signaling response characterization, and titration strategy optimization use this concentration to support comprehensive escalation protocol designs without logistical interruption.
Reconstitute lyophilized Tirzepatide 30mg with sterile bacteriostatic water using GMP-compliant sterile laboratory technique. Typical reconstitution volumes range from 2–4ml depending on the target working concentration and experimental design requirements. All preparation steps should be documented in accordance with institutional laboratory standards and research record-keeping protocols. Use calibrated equipment throughout preparation.
Store lyophilized peptide at 2–8°C in a dark, temperature-controlled laboratory environment prior to reconstitution. Following reconstitution, maintain strict refrigeration at 2–8°C to preserve dual-agonist peptide stability. Cold-chain shipping is not required, but immediate refrigeration upon receipt is recommended to ensure optimal peptide integrity throughout the protocol period. Each Elivena vial is supplied with COA documentation and handling guidance.
Institutional research programs may extend 52–104 weeks for comprehensive dual-agonist receptor characterization across multiple protocol phases. Studies systematically monitor incretin signaling pathway panels, receptor activity markers, and molecular endpoint expression at defined experimental intervals. The 30mg concentration supports uninterrupted long-term study execution with consistent, reliable peptide availability across all concurrent protocol arms.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
A synthetic 44-amino acid analog of growth hormone-releasing hormone studied for pituitary receptor binding kinetics, GHRH pathway signaling dynamics, and downstream somatotropic axis marker activity in controlled preclinical models.
Research-grade synthetic peptide formulated in mid-range 10mg quantity for cellular migration studies and peptide actin-binding research in controlled laboratory environments.
A high-concentration, long-acting GLP-1 receptor agonist studied for incretin pathway receptor pharmacology, downstream cAMP signaling cascade dynamics, and multi-arm metabolic endpoint marker quantification in extended institutional research protocols.
A synthetic GHRH analog studied for receptor binding kinetics, molecular interaction modeling, and pulsatile signaling pathway investigation in preclinical settings.
Research-grade synthetic peptide fragment formulated for advanced laboratory peptide research and experimental scientific protocols. Disclosure: This product is intended for research purposes only and is not intended for human consumption...
